Navigating the new normal: Debating the place of high-efficacy vs escalation treatment approaches in multiple sclerosis

18 November 2020

18:00–19:00 GMT

Job bag: MUL20-E063h | Date of preparation: November 2020

This meeting is organised and funded by Novartis Pharmaceuticals UK Limited

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the Patient Safety Information (PSI) tool at https://report.novartis.com

If you have a question about a Novartis product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com

To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.